ArticleACS omega2025
Gas-Phase Electrophoresis (nES GEMMA Instrumentation) of SARS-CoV-2-Based Virus-like Particles.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gas-phase electrophoresis separates singly charged particles according to their size at ambient pressure in a high laminar sheath flow of particle-free air and a tunable electric field. Subsequent detection of analytes is particle-number-based. Such a setup is very robust and has been successfully applied for several (bio)-nanoparticle-containing materials, e.g., virus-like particles (VLPs). These resemble their parent viruses but due to lack of genomic material are noninfectious. Hence, VLPs find great interest, e.g., in the fields of vaccine development, shielded cargo transport, gene therapy, or parent virus characterization. In all those cases, information on particle size, size distribution, analyte stability, particle numbers, and particle-size derived molecular weight (MW) values yields valuable insights into the VLP in question. Focusing on SARS-CoV-2 VLPs, the source of the recent COVID-19 pandemic, we demonstrate for the first time that gas-phase electrophoresis on a nES GEMMA (nano-electrospray gas-phase electrophoretic mobility molecular analyzer) also known as nES DMA (differential mobility analyzer) or SMPS instrument is possible. VLPs can be detected as broad, size-heterogeneous peaks next to low MW material. Host-cell proteins as well as VLP building blocks can thus be analyzed with the same setup as native macromolecules. Therefore, nES GEMMA measurements are able to support characterization of SARS-CoV-2 VLP-containing samples in terms of VLP stability, particle size, number concentration, and MW values (based on a MW/nES GEMMA-derived particle size correlation).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.